Travere Therapeutics (TVTX)VA awarded $33K

$33K

committed so far

Signed

Jul 30, 2026

Updated

Jul 30, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 1, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
2. Jun 12, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the “Retirement Date”), the 10 year anniversary of his employment with the Company.”
3. Jun 24, 2026Federal contract · $16K obligatedDepartment of Veterans Affairs awarded Travere Therapeutics, Inc.: $16K obligated to date
4. Jul 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company’s Annual Report on Form 10-K expected in February 2027 (the “Retirement Date”).”
5. Jul 10, 2026Federal contract · $16K obligatedDepartment of Veterans Affairs awarded Travere Therapeutics, Inc.: $16K obligated to date
6. Jul 30, 2026 · this disclosureFederal contract · $33K obligatedDepartment of Veterans Affairs awarded Travere Therapeutics, Inc.: $33K obligated to date

What came next

1. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 5, 2026Federal contract · $16K obligatedDepartment of Veterans Affairs awarded Travere Therapeutics, Inc.: $16K obligated to date
3. Sep 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 21, 2026, Travere Therapeutics, Inc. (the “Company”) and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the Company effective as of December 1, 2026 (the “Officer Resignation Date”).”

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for Travere Therapeutics

For Travere Therapeutics, OQRO holds 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TVTX page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at Travere Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• USAspending.gov award recordAug 5, 2026
• SEC Form 13F-HRJul 29, 2026
• USAspending.gov award recordJul 10, 2026

Everything OQRO holds on this company is on its TVTX page.